Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elisa Agostinetto

Showing results (61-70 of 76) with videos related to

Pageof 8
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 22, 2025
Molecular and clinical analyses of gene fusions identify therapeutic targets in paired primary and metastatic breast cancer from the AURORA program (BIG 14-01)Chiara Biagioni, Danai Fimereli, Alexandre Irrthum, et al.
Frontiers in Immunology|June 5, 2026
Long-term immune response to mRNA anti-SARS-CoV-2 vaccination in patients with cancerSoraia Lobo-Martins, Diogo Martins-Branco, Francine Padonou, et al.
Clinical Breast Cancer|June 7, 2025
Real-World 5-Year Outcomes of Patients Treated With the Adjuvant Paclitaxel Trastuzumab (APT) Regimen for Stage I HER2-Positive Early Breast Cancer: A Retrospective International StudySoraia Lobo-Martins, Veronique Debien, Elisa Agostinetto, et al.
Breast (Edinburgh, Scotland)|April 5, 2025
Clinical characteristics and prognostic factors in patients with breast cancer and leptomeningeal metastases from a large registry of BMBCElena Laakmann, Marcus Schmidt, Kristina Lübbe, et al.
Eclinicalmedicine|May 31, 2023
Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: an individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studiesMatteo Lambertini, Eva Blondeaux, Giancarlo Bisagni, et al.
Therapeutic Advances in Medical Oncology|December 22, 2023
Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitorsEmma Zattarin, Luigi Mariani, Alice Menichetti, et al.
Nature Communications|November 3, 2023
Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trialLaurence Buisseret, Delphine Loirat, Philippe Aftimos, et al.
NPJ Breast Cancer|April 17, 2023
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitorsEmma Zattarin, Daniele Presti, Luigi Mariani, et al.
European Journal of Cancer (Oxford, England : 1990)|April 29, 2025
Assisted reproductive technology in young BRCA carriers with a pregnancy after breast cancer: An international cohort studyIsotta Martha Magaton, Eva Blondeaux, Anne-Sophie Hamy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2021
Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor-Positive Advanced Breast Cancer (EVERMET)Claudio Vernieri, Federico Nichetti, Luca Lalli, et al.
Pageof 8

Showing results (61-70 of 76) with videos related to

Sort By:
Pageof 8
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 22, 2025
Molecular and clinical analyses of gene fusions identify therapeutic targets in paired primary and metastatic breast cancer from the AURORA program (BIG 14-01)Chiara Biagioni, Danai Fimereli, Alexandre Irrthum, et al.
Frontiers in Immunology|June 5, 2026
Long-term immune response to mRNA anti-SARS-CoV-2 vaccination in patients with cancerSoraia Lobo-Martins, Diogo Martins-Branco, Francine Padonou, et al.
Clinical Breast Cancer|June 7, 2025
Real-World 5-Year Outcomes of Patients Treated With the Adjuvant Paclitaxel Trastuzumab (APT) Regimen for Stage I HER2-Positive Early Breast Cancer: A Retrospective International StudySoraia Lobo-Martins, Veronique Debien, Elisa Agostinetto, et al.
Breast (Edinburgh, Scotland)|April 5, 2025
Clinical characteristics and prognostic factors in patients with breast cancer and leptomeningeal metastases from a large registry of BMBCElena Laakmann, Marcus Schmidt, Kristina Lübbe, et al.
Eclinicalmedicine|May 31, 2023
Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: an individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studiesMatteo Lambertini, Eva Blondeaux, Giancarlo Bisagni, et al.
Therapeutic Advances in Medical Oncology|December 22, 2023
Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitorsEmma Zattarin, Luigi Mariani, Alice Menichetti, et al.
Nature Communications|November 3, 2023
Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trialLaurence Buisseret, Delphine Loirat, Philippe Aftimos, et al.
NPJ Breast Cancer|April 17, 2023
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitorsEmma Zattarin, Daniele Presti, Luigi Mariani, et al.
European Journal of Cancer (Oxford, England : 1990)|April 29, 2025
Assisted reproductive technology in young BRCA carriers with a pregnancy after breast cancer: An international cohort studyIsotta Martha Magaton, Eva Blondeaux, Anne-Sophie Hamy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2021
Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor-Positive Advanced Breast Cancer (EVERMET)Claudio Vernieri, Federico Nichetti, Luca Lalli, et al.
Pageof 8